《大佛药业怎么样》

大佛药业，作为一家在医药领域具有一定影响力的企业，备受关注。

深圳大佛药业股份有限公司是一家中外合资企业，成立于 1994 年，注册资本为 3000 万元。公司位于深圳市生物医药创新产业园区，是国内少数专注于喷雾剂、吸入制剂生产的企业。它拥有先进的生产检验设备、成熟的技术工艺体系以及完善的质量管理体系。

公司的产品丰富多样，主要有盐酸羟甲唑啉喷雾剂、硫酸沙丁胺醇雾化吸入溶液、鲑鱼降钙素喷鼻剂和高渗海水鼻腔喷雾器等。其中，公司的多个产品具有较好的资质条件，多为独家生产，多属国内首仿，多个产品还获得了深圳市科学技术研究成果登记证书。此外，大佛药业有 2 个产品被列入国家基本药物目录，1 个产品被列入国家低价药目录，4 个产品被列入国家医保目录。

在销售方面，大佛药业实行“处方零售互动，直营招商并存”的销售模式，采用直营和招商相结合的方式，分事业部拓展处方市场和零售市场。目前，公司产品在处方市场覆盖的医院超过 2000 家，在零售市场覆盖的药店超过 15000 家。公司坚持学术营销与品牌营销相结合的市场推广模式，在耳鼻喉及呼吸系统市场具有较高的品牌知名度。

在人员结构和工作氛围方面，公司拥有一支专业化的营销队伍，在二十多个省市设立了办事处，形成了覆盖全国的高效运作的销售网络。不过，据反馈，有 4 票表示经常加班。

从招聘需求来看，其增长速度为-32%，2021 年比 2020 年少 7 个职位。薪酬区间为 4.5K - 15K，最多人拿 4.5K - 6K。

总的来说，大佛药业在医药行业中具有一定的地位和优势，但也存在一些需要改进和完善的地方。

"How is Dafo Pharmaceutical?"

Dafo Pharmaceutical, as an enterprise with certain influence in the field of medicine, has attracted much attention.

Shenzhen Dafo Pharmaceutical Co., Ltd. is a Sino-foreign joint venture established in 1994 with a registered capital of 30 million yuan . The company is located in the Shenzhen Biomedical Innovation Industrial Park and is one of the few domestic enterprises focusing on the production of sprays and inhalation preparations. It has advanced production and inspection equipment, a mature technical process system and a complete quality management system.

The company has a rich variety of products, mainly including Oxymetazoline Hydrochloride Spray, Salbutamol Sulfate Nebuliser Solution, Salmon Calcitonin Nasal Spray and Hypertonic Seawater Nasal Spray, etc. Among them, many of the company's products have good qualification conditions, most of which are produced exclusively and are the first imitations in China. Many products have also obtained the registration certificates of scientific and technological research achievements in Shenzhen. In addition, two of Dafo Pharmaceutical's products have been included in the National Essential Drug List, one product has been included in the National Low-price Drug List, and four products have been included in the National Medical Insurance List.

In terms of sales, Dafo Pharmaceutical implements a sales model of "interaction between prescription and retail, coexistence of direct sales and investment promotion", and adopts a combination of direct sales and investment promotion to expand the prescription market and retail market through divisions. At present, the company's products cover more than 2,000 hospitals in the prescription market and more than 15,000 pharmacies in the retail market. The company adheres to the market promotion model combining academic marketing and brand marketing, and has a high brand awareness in the otorhinolaryngology and respiratory system market.

In terms of personnel structure and working atmosphere, the company has a professional marketing team and has set up offices in more than 20 provinces and cities, forming a highly efficient sales network covering the whole country. However, according to feedback, 4 votes indicated frequent overtime work.

From the perspective of recruitment demand, its growth rate is -32%, and there were 7 fewer positions in 2021 than in 2020. The salary range is 4.5K - 15K, and most people get 4.5K - 6K.

In general, Dafo Pharmaceutical has a certain position and advantages in the pharmaceutical industry, but there are also some areas that need improvement and refinement.